Skip to main content
GSK
NYSE Life Sciences

GSK's Bepirovirsen NDA Accepted for Review in China for Chronic Hepatitis B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$54.3
Mkt Cap
$108.6B
52W Low
$32.38
52W High
$61.695
52W Position info
68% above low
Off High info
12% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

GSK sits 68% above its 52-week low of $32.38.

Summary

GSK announced that China's NMPA has accepted its New Drug Application for bepirovirsen, a potential first-in-class functional cure for chronic hepatitis B, supported by positive Phase III trial results.


Key Events · Product Development and Regulatory · GSK

  • Regulatory Acceptance in China

    China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for bepirovirsen for the treatment of adults with chronic hepatitis B (CHB).

  • Potential First-in-Class Functional Cure

    Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed as a potential first-in-class functional cure for CHB, a condition with low functional cure rates from current standard of care.

  • Significant Market Opportunity

    Chronic hepatitis B affects an estimated 75 million people in China, representing a substantial patient population for this potential new treatment.

  • Supported by Positive Phase III Data

    The regulatory submission is backed by statistically significant and clinically meaningful functional cure rates demonstrated in the pivotal Phase III B-Well 1 and B-Well 2 trials.


Analysis · GSK · Life Sciences

This filing marks a significant regulatory advancement for GSK's bepirovirsen in a critical market, following its recent acceptance for review by the EMA. The drug, which has Breakthrough Therapy designation in China, targets chronic hepatitis B, a condition affecting an estimated 75 million people in China with high mortality rates. The NDA acceptance, based on strong Phase III data, positions bepirovirsen as a potential first-in-class functional cure, offering a significant improvement over current treatments that have low functional cure rates. This development enhances GSK's pipeline value and future revenue potential in a large, underserved patient population.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GSK was trading at $54.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $108.6B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GSK - Latest Insights

GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $50.25 info
Change: +$1.50 (+3%) info
Market Cap: $101.206B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $50.25 info
Change: +$1.17 (+2%) info
Market Cap: $101.206B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $50.25 info
Change: -$0.950 (-2%) info
Market Cap: $101.206B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $50.25 info
Change: -$0.865 (-2%) info
Market Cap: $101.206B info
GSK
Oct 26, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.04
Real-time Price: $50.25 info
Change: -$0.790 (-2%) info
Market Cap: $101.206B info